Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.94 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.94 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.81 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | CES2 | O00748 | 2/20 | 0.62 |
| ▸ | CES1 | P23141 | 2/20 | 0.62 |
| ▸ | RXRA | P19793 | 1/20 | 0.58 |
| ▸ | RXRB | P28702 | 1/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 4/20 | 0.56 |
| ▸ | CA2 | P00918 | 4/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA3 | P07451 | 1/20 | 0.55 |
| ▸ | TYR | P14679 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA6 | P23280 | 1/20 | 0.55 |
| ▸ | CA5A | P35218 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4-Chloro-Benzoic Acid SCHEMBL1331727 | 0.97 | TSHR (1.00) | TSHRALOX15SRD5A2TP53ALDH1A1 | |
| 4-Chloro-Benzoic Acid SCHEMBL28384 | 0.97 | TSHR (1.00) | TSHRALOX15SRD5A2TP53ALDH1A1 | |
| 4-Chloro-Benzoic Acid SCHEMBL32665742 | 0.94 | TSHR (0.94) | TSHRALOX15SRD5A2TP53ALDH1A1 | |
| 4-Chloro-Benzoic Acid SCHEMBL7634885 | 0.94 | TSHR (0.94) | TSHRALOX15SRD5A2TP53ALDH1A1 | |
| 4-Chloro-Benzoic Acid SCHEMBL29191317 | 0.94 | TSHR (0.94) | TSHRALOX15SRD5A2TP53ALDH1A1 | |
| 4-Chloro-Benzoic Acid SCHEMBL3150134 | 0.94 | TSHR (0.94) | TSHRALOX15SRD5A2TP53ALDH1A1 | |
| 4-Chloro-Benzoic Acid SCHEMBL2918294 | 0.94 | TSHR (0.94) | TSHRALOX15SRD5A2TP53ALDH1A1 | |
| 4-Chloro-Benzoic Acid SCHEMBL11173042 | 0.94 | TSHR (0.94) | TSHRALOX15SRD5A2TP53ALDH1A1 | |
| 4-Chloro-Benzoic Acid SCHEMBL9120766 | 0.94 | TSHR (0.94) | TSHRALOX15SRD5A2TP53ALDH1A1 | |
| 4-Chloro-Benzoic Acid SCHEMBL8024007 | 0.94 | TSHR (0.94) | TSHRALOX15SRD5A2TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243137-A1 | METHOD FOR PREPARING 3-CHLOROBICYCLO[3.2.1]-3-OCTEN-2-OL | SHANDONG WEIFANG RAINBOW CHEMICAL CO.,LTD (CN) | 2025-07-31 | — | — | US | claimed |
| WO-2024152641-A1 | PREPARATION METHOD FOR 3-CHLOROBICYCLO[3.2.1]-3-OCTEN-2-OL | 山东潍坊润丰化工股份有限公司 | 2024-07-25 | — | — | WO | claimed |
| CN-115784837-A | Preparation method of 3-chlorobicyclo [3.2.1] -3-octen-2-ol | 山东潍坊润丰化工股份有限公司 | 2023-03-14 | — | — | CN | claimed |
| US-20250243137-A1 | METHOD FOR PREPARING 3-CHLOROBICYCLO[3.2.1]-3-OCTEN-2-OL | SHANDONG WEIFANG RAINBOW CHEMICAL CO.,LTD (CN) | 2025-07-31 | — | — | US | disclosed |
| CN-116514635-B | Process for preparing 3-chlorobicyclo [3.2.1] -3-octen-2-ol | 山东潍坊润丰化工股份有限公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2024152641-A1 | PREPARATION METHOD FOR 3-CHLOROBICYCLO[3.2.1]-3-OCTEN-2-OL | 山东潍坊润丰化工股份有限公司 | 2024-07-25 | — | — | WO | disclosed |
| CN-116514635-A | Process for preparing 3-chlorobicyclo [3.2.1] -3-octen-2-ol | 山东潍坊润丰化工股份有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-115784837-B | Process for preparing 3-chlorobicyclo [3.2.1] -3-octen-2-ol | 山东潍坊润丰化工股份有限公司 | 2023-04-25 | — | — | CN | disclosed |
| CN-115784837-A | Preparation method of 3-chlorobicyclo [3.2.1] -3-octen-2-ol | 山东潍坊润丰化工股份有限公司 | 2023-03-14 | — | — | CN | disclosed |
| US-10239833-B2 | Intermediates, their process and use in preparation of selective α1-adrenoceptor antagonists, Silodosin | MANKIND PHARMA LTD. (IN) | 2019-03-26 | — | — | US | disclosed |
| US-20180111901-A1 | Novel Intermediates, their Process And Use In Preparation of Selective a1-Adrenoceptor Antagonists, Silodosin | MANKIND PHARMA LTD. (IN) | 2018-04-26 | — | — | US | disclosed |
| US-9862681-B2 | N-haloalkylindoline intermediates, their process and use in preparation of Silodosin and its derivatives | MANKIND RESEARCH CENTRE (IN) | 2018-01-09 | — | — | US | disclosed |
| US-20160046577-A1 | N-Haloalkylindoline Intermediates, Their Process And Use In Preparation of Silodosin And its Derivatives | MANKIND PHARMA LTD (IN) | 2016-02-18 | — | — | US | disclosed |
| EP-2984070-A1 | N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES | Mankind Research Centre (IN) | 2016-02-17 | — | — | EP | disclosed |
| WO-2014167507-A1 | N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES | MANKIND RESEARCH CENTRE (IN) | 2014-10-16 | — | — | WO | disclosed |
| CN-101070300-B | Linonene anologs and its preparing method and use | UNIV SHENYANG PHARMACEUTICAL | 2011-06-01 | — | — | CN | disclosed |
| CN-101070300-A | Linonene anologs and its preparing method and use | UNIV SHENYANG PHARMACY (CN) | 2007-11-14 | — | — | CN | disclosed |
| US-5185471-A | Reacting 5-halo-2-nitrobenzotrifluorides with inorganic base to form 1,1*-oxy-Bis(3-trifluoromethyl-4-nitrobenzen using benzoate catalyst | OCCIDENTAL CHEMICAL CORPORATION (US) | 1993-02-09 | — | — | US | disclosed |
| EP-0509241-A2 | A novel method for ether formation | OCCIDENTAL CHEMICAL CORPORATION (US) | 1992-10-21 | — | — | EP | disclosed |
| US-4723016-A | Preparation of anhydrous organic acid salts | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239833-B2 | Intermediates, their process and use in preparation of selective α1-adrenoceptor antagonists, Silodosin | ADRA1D, ADRB1, ADRA1A | TSHR 1201/4885ALOX15 1308/4885SRD5A2 90/4885 |
| US-20250243137-A1 | METHOD FOR PREPARING 3-CHLOROBICYCLO[3.2.1]-3-OCTEN-2-OL | OSTC, HAO2, ODC1 | TSHR 2467/4885ALOX15 370/4885SRD5A2 271/4885 |
| US-20160046577-A1 | N-Haloalkylindoline Intermediates, Their Process And Use In Preparation of Silodosin And its Derivatives | ADRA1D, ADRA1A, ADRB1 | TSHR 1400/4885ALOX15 1417/4885SRD5A2 400/4885 |
| US-20180111901-A1 | Novel Intermediates, their Process And Use In Preparation of Selective a1-Adrenoceptor Antagonists, Silodosin | ADRA1D, ADRA1A, ADRB1 | TSHR 1180/4885ALOX15 907/4885SRD5A2 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.